AOB

[la-onda]

sound good IMO

American Oriental Bioengineering, Inc. Announces Preliminary Results for Third Quarter 2006
Monday October 23, 9:24 am ET
-- Company Expects to Report Revenue of Approximately $27 million for Third Quarter and EPS of at least $0.11; Representing 102% and 38% Increase from Last Year
-- Earnings Conference Call Scheduled for November 14, 2006 at 4:45 PM EST to Discuss Final Results

NEW YORK--(BUSINESS WIRE)--American Oriental Bioengineering, Inc. (AMEX: AOB - News), a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products in China, today announced preliminary results for the third quarter 2006 and the date for the Company's third quarter conference call to discuss final results.

The Company expects to report revenue of approximately $27 million for the third quarter 2006, which would represent a 102 percent increase from the third quarter of last year based on continued strength across all major product lines. AOB expects to report earnings per share of at least $0.11 for the third quarter 2006, which would represent 38 percent increase from last year.

Management will conduct a conference call on November 14, 2006 to announce final third quarter 2006 results. During that time management will provide further financial details in regards to the third quarter.

The conference call will take place at 4:45 p.m. ET. Interested participants should call 888-243-1152 when calling within the United States or 973-582-2868 when calling internationally. There will be a playback available until Nov 21, 2006. To listen to the playback, please call 877-519-4471 when calling within the United States or 973-341-3080 when calling internationally. Please use pass code 8024117 for the replay.

This call is being webcast by ViaVid Broadcasting and can be accessed at American Oriental Bioengineering's Web site at http://www.bioaobo.com. The webcast may also be accessed at ViaVid's Web site at www.viavid.net. The webcast can be accessed until December 14, 2006 on either site.

[la-onda]

marketwatch quotation:
American Oriential Bioengineering
AOB7.50, +0.21, +2.9% ) , too, has recently broken out of a long base, which in this case was a one-year coiling pattern. The break began at the end of September in the 5 area and took the stock to a nominal new all-time high just under 8 last week before backing off on Thursday and Friday. AOB had an even larger percentage run back in 2005 when it exploded off the May 2005 bottom near 1 and ran up nearly eight-fold in six months before the one-year coiling consolidation began. Often the longer the base, the bigger the breakout, and the stock's long breathing period has given it, in our view, additional room to run. Our short-term trading target is 9, intermediate target 12, and longer-term target around 15 or so. Short-term support is around the 6.5 to 7 zone.

http://www.marketwatch.com/News/Story/Story.aspx?guid=%7B58C66FED%2DD616%2D4CCE%2DBB24%2DC69344E4F45A%7D&source=blq%2Fyhoo&dist=yhoo&siteid=yhoo

[la-onda]

up again...

[la-onda]

wow 

American Oriental Bioengineering Inc. Reports Record Quarterly Revenue and Earnings and Provides Guidance for Fourth Quarter 2006
Business Wire - November 14, 2006 4:01 PM ET

Related Quotes
Symbol         Last    Chg
AOB    Trade    8.43    +0.04
Real time quote.


American Oriental Bioengineering Inc. (AMEX: AOB)

Third Quarter 2006 Highlights:

-- Organic Revenue Growth of 63% during the Quarter

-- Consolidated Gross Margins improve 3.5% versus last year to 66.9%

-- Management Expects Fourth Quarter Revenue to be in the range of $37 million to $39 million and at least $0.15 in EPS

American Oriental Bioengineering Inc. (AMEX: AOB), a leading Chinese manufacturer and distributor of plant-based pharmaceutical and nutraceutical products, today announced financial results for the third quarter ended September 30, 2006.

Key Financial Indicators
(All numbers in thousands, except per-share amounts in USD)

                                     Q32006    Q32005   Percent Change

Revenues                            $27,075   $13,407       101.9%
Cost of goods sold                  $ 8,975   $ 4,912       82.7%
Gross Profit                        $18,099   $ 8,495       113.1%
Total Operating Expenses            $ 8,746   $ 3,857       126.8%
Income from Operations              $ 9,353   $ 4,639       101.6%
Net Income                          $ 7,551   $ 3,710       103.5%
EPS--Fully Diluted                  $  0.12   $  0.08       50.0%


The U.S. Dollar amounts are calculated based on the average conversion rate of US $1 to 7.9087 RMB for the third quarter 2006 and US $1 to 8.0920 RMB for the third quarter 2005.

Third Quarter 2006 Results

For the third quarter 2006, the Company reported revenues of $27.1 million, an increase of 101.9 percent compared to $13.4 million in the third quarter of last year. The increase in total revenues for the quarter from last year was driven by strong organic growth in the Company's Plant-based Pharmaceutical (PBP) and Plant-based Nutraceutical (PBN) line of products and as a result of continuing momentum from the acquisition of Guangxi Lingfeng Pharmaceutical Co. Ltd. (GLP) earlier this year. During the third quarter, PBP sales, including GLP products, increased by 130.5 percent to $19.9 million compared to the third quarter last year. Sales of the Company's Cease Enuresis Soft Gel and Patch increased 117.8 percent to $6.6 million as compared to last year with sales of the Company's Shuanghuanlian Injection Powder increasing 51.5 percent to $6.5 million. GLP revenues totaled $5.2 million which improved 72 percent sequentially as compared to the second quarter 2006. There were no revenues from GLP during the third quarter of last year. Sales of PBN products in the third quarter 2006 totaled $7.2 million, representing a 50.3 percent increase from $4.8 million last year. PBN sales benefited from growth in several of the Company's products with the greatest impact as a result of an 82.4 percent increase versus the comparable quarter last year in the sale of Protein Peptide series products to $6.4 million. The Company continues to benefit from increased marketing efforts leading to better brand awareness and increased penetration.

"I am pleased to report that our business continues to experience strong momentum as we reported the highest quarterly revenue and net income in the Company's history as we continue to penetrate the Chinese market and reinvigorate consumer brand awareness for GLP products in the women's health market," commented Tony Liu, Chairman and CEO of AOB. "We are pleased with the performance of our most recent initiatives, which include increased advertising and the expansion of our distribution channels through the acquisition of HQPL, as AOB becomes a recognized brand across China. We believe our orders for GLP products scheduled for delivery in the fourth quarter will exceed our projection of $6 million announced at the end of September."

Cost of goods sold were $9.0 million during the third quarter, representing an increase of 82.7 percent, compared to $4.9 million in the same period last year. Gross margins for the period were 66.9 percent compared to 63.4 percent last year as the Company improved gross margins through operating cost management, sourcing and an increase in operational efficiencies.

Total operating expenses for the third quarter were $8.8 million which represented an increase of 126.8 percent versus last year as the Company experienced growth in all expense items to support revenue growth. Advertising expense increased the largest on an absolute dollar and percentage basis to $3.6 million which was up 376.8 percent versus the comparable quarter last year as the Company looked to reinforce the benefits of its key PBP and PBN products in the market. Selling and marketing expense increased 162.4 percent to $2.2 million as the Company increased several functions consistent with further growth in the business. General and administrative expenses increased 14.6 percent year over year to $2.2 million and decreased as a percentage of sales to 8.2 percent compared to 14.5 percent last year as management diligently controlled expense in this area and improved overall efficiency. As a result of strong revenue growth and gross margin expansion operating income increased 101.6 percent versus the comparable quarter last year to $9.4 million. Operating margins were 34.5 percent for the quarter which was relatively unchanged from last year but improved 3.8 percent from the second quarter 2006.

The Company's income tax rate decreased slightly to 20.2 percent compared to 23.3 percent last year as the Company benefited from favorable tax treatment surrounding the acquisition of GLP. Net income increased to 103.5 percent to $7.6 million or $0.12 per fully diluted share compared to $3.7 million or $0.08 last year. Earnings per share increased 50 percent versus the third quarter 2005.

For the nine month period ending September 30, 2006 revenues increased 98.0 percent to $69.2 million. Organic growth, which excludes the contribution from GLP, was 74.5 percent. PBP revenues increased 118.6 percent to $48.2 million. PBN revenues increased 62.9 percent to $21.0 million. Gross profit increased 107.1 percent to $46.0 million with gross margins of 66.5 percent compared to 63.6 percent last year. Gross margins increased as a result of the factors mentioned previously. Operating income for the nine month period was $22.8 million representing an 87.7 percent increase with operating margins of 32.9 percent as compared to 34.7 percent last year. Net income increased 99.1 percent to $18.4 million or $0.30 per weighted average fully diluted share compared to $9.2 million or $0.22 per weighted average fully diluted share for the comparable period last year. Earnings per share increased over 36 percent for the period.

The Company completed the quarter with $71.9 million in cash which increased $14.3 million from the end of 2005. Total debt at the end of the third quarter was $11.0 million versus $3.7 million at the end of 2005 with the increase primarily as a result of the GLP acquisition. Inventory increased 19.8 percent to $12.6 million versus the third quarter last year. Accounts receivable increased 24.3 percent to $9.6 million with respective Days Sales Outstanding (DSO) decreasing 30 days from the third quarter 2005 to 32 days. As a result of a significant increase in net income through the first nine months of 2006 and improving working capital management, cash flow from operations was $15.1 million with respective free cash flow of $11.8 million. Shareholders equity improved 55.9 percent from the end of 2005 to $141.2 million.

Mr. Liu concluded, "Based on improving visibility and confidence in our business we are going to begin providing quarterly revenue and earnings per share guidance beginning with our fourth quarter 2006 results. At this time we expect the fourth quarter revenue to be in the range of $37 million to $39 million with diluted earnings per share of at least $0.15, which would represent approximately 88 percent to 98 percent revenue growth from the comparable quarter last year with EPS increasing approximately 67 percent versus last year."

Based on the Company's fourth quarter 2006 financial expectations, revenue for the 2006 fiscal year is anticipated to be in the range of $106 million to $108 million. Fiscal 2006 EPS is anticipated to be at least $0.45 per fully diluted share.

[la-onda]

is this a high flat pattern ?

[usedcasting]

This one should really have been for the long term. I reccomended it to my Dad (Mr Long term) at the time and he just now doubled his money. Thanks for the heads up Dave.

uc.

[valueseeker]

The little $2 stock is now $12.09. I was in $2.5, sold at $7.4. Back @9.5 and holding for the new highs on NYSE.

[rurouni]

AOB seems to have a lot of juice.  I have been following this stock for a while.

Smart money upgraded their target to $16.  Any comments on Brean Murray stock rating credibility?

http://www.smartmoney.com/eqsnaps/index.cfm?story=ratings&symbol=AOB

What do you guys think?

[snowcat]

From Mr. Market - entertaining, but usually the kiss of death:

Ever go out drinking all night and come home tired with a belly full of
beer?  Everything is excellent and you are more than prepared to sleep
like a baby.  You throw your clothes all over the room and then dive
into bed.  Another Saturday night success! 

All of a sudden you start having these weird dreams.  YouÂ're driving
in a car and need to pull over to the side of the road to go siss.  Or,
youÂ're at a football game and you get up to go to the menÂ's room and
you canÂ't find it.  Or youÂ're back in high school, and you ask the
teacher for a hall pass, and he doesnÂ't give it to you.  Finally, you
wake up with the revelation that you have to go siss like a Russian race
horse.  So you go to your bathroom, open up your fire hose, take care
of bitness and go try to go back to sleep.  The only problem is that now
your head is throbbing like 10 pounds of poop in a 3 pound bag.

Or how about this scenario?  You schedule a morning meeting at 10 am. 
This way you get to sleep an extra hour.  But at 6 am, you get that
urge to go siss.  You get up and take care of bitness, but now you canÂ't
go back to sleep.

Or how about this story?  Titan Omega went up on the roof to siss.   He
gets too close to the edge and takes the fast elevator down.

Or how about this story?  A Yale graduate and a Wharton MBA wakes up in
the middle of the night, sleepwalks to his refrigerator and waters his
lettuce.

http://images.blogstream.com/i/userImages/23/23025_6501.jpg

All of these stories are true and truth IS stranger than fiction.

WouldnÂ't it be great if there were some ancient Chinese herb you could
take to make you suppress the urge to go siss when you donÂ't really
have to?  Now you donÂ't have to dream.

Today I bought AOB, American Oriental Bioengineering, at 12.25.  I will
sell it in 4 - 6 weeks 14.15.  HereÂ's why I like AOB:

AOBÂ's stock is up 184% in the last 12 months, yet itÂ's still very
cheap.  Even though its present P/E is 33, itÂ's accelerating growth and
earnings puts its forward P/E ratio at only 22.   Look at this
chartÂ...itÂ's ramping up:

http://chart.finance.yahoo.com/c/1y/a/aob

American Oriental Bioengineering, Inc. engages in the development and
production of plant-based pharmaceutical (PBP) products and plant-based
nutraceutical (PBN) products in China. Its PBP products include cease
enuresis soft gel, which is used to alleviate bed-wetting and urination
disorder; double ginseng yishen grain that is used for neurosis,
vegetative nerve functional disturbance, and hypo-immunity; root of
red-rooted salvia tablet that improves blood circulation and blood flow to the
coronary artery to relieve pain, and is used for coronary ischemia and
angina pectoris caused by coronary heart disease; and urinstopper patch,
which is used to avoid frequent urination, urinal incontinence, and bed
wetting.

Their two big products are SoyPeptide Beverage.  The product contains
Soybean Peptide which is extracted from the Soy Protein Isolate through
enzyme reaction, is composed of 3 to 6 amino acid with molecular weight
less than 1,000d. Peptide is absorbed and digested by our body more
directly than amino acid, is low in sensitivity and zero in cholesterol
that is good to health. It also consists of complete plant protein, rich
in 9 kinds of essential amino acids that make rapid recovery of energy,
as well as accelerating the power of brain. Further, it is also good
for energy metabolism. This product is added with soybean peptide and
condensed ribes nigrum, which is rich in vitamins and minerals, is very
good to our health.

The other one is  Cease-enuresis soft gel
Chinese spelling：Yiniaoting Jiaonang
Ingredientsã€'Hulled seed cream of shinyleaf yellowhorn.
Characterã€' This products are in brown granules, slightly sweet and
acerbity in flavor
Pharmacological actionã€' This product can reduce micturition times of
water loading in mice; increase sphincter vesicae discharge frequency
of a rat, enlarging scope,as well as prolong discharge period, as a
result shrink sphincter vesicae. The in vitro studies  indicated this
product also can resist the shrinkage of white rat's bladder smooth muscle
caused by acetylcholine, as well as reduce its tension.  What?  No more
shrinkage?  Now I can go in the pool?

We all agree that medicine is getting expensive.  People, wisely, will
turn to non-prescription herbal products if they work.  How do you know
if they work?  Word of mouth is the tried and true way.  This stuff
actually seems to be working.  How do I know this?  Do people buy Ipods? 
People are buying AOBÂ's products.  It seems to work, and people like
telling their friends about it, especially if it works.

AOB has, in the last ten years, grown from a start-up in 1994 with
about $100,000 of revenue to become a leading manufacturer of plant-based
pharmaceutical products and plant-based nutraceutical products for the
rapidly growing Chinese market.  They operate in a large and growing
market. The total pharmaceutical and nutraceutical market in China was
approximately $62 billion in 2004. Demographic trends in this market are
favorable, as the Chinese population continues to grow and age and
economic expansion in China creates wealth, which serves to increase the
number of citizens who can afford healthcare. With the total market for
pharmaceutical products in China, herbal and plant-based pharmaceutical
remedies and products have an extensive history. Many Chinese consumers
and doctors rely upon the use of plant-based products for treatment of
a variety of different ailments, consistent with the Eastern philosophy
of health and wellness.   AOB's standing could open the way to a raft
of new biotech developed foods in China, particularly as the country
races to meet rising demand for processed foods in an effort to feed its
still burgeoning population – currently said to stand at 1.3 billion
people. The supply of soy products has proved particularly problematic in
recent years, leading the country to become a net importer of soybeans.

The company's research team reports that the growth of liver cancer
cells inside mice was Â'successfully suppressed' by soybean protein
peptides without side effects. Their findings could lead to future market
opportunities for the ingredient.  Soy is the most widely used botanical
by pre- and post-menopausal women but its use by men is also growing as
research continues to show the benefits on heart health. In the US, soy
sales have grown from $940 million in 1990 to a projected $4 billion
this year.

AOB currently has more than 100 products in their portfolio, all
plant-based in formulation divided into two key categories: plant-based
pharmaceuticals and plant-based nutraceuticals. PBP is the larger of the
CompanyÂ's two divisions as a percentage of revenue. PBP products in China
require approval from the state FDA and are administered both through
over-the-counter locations and through prescriptions at hospitals and
clinics. The two largest products in the PBP category are Shuanghuanglian
Powder Injection and Cease Enuresis Soft Gel. SLPI, our largest
contributing product, as a percent of total revenue is one of the only two PBP
herbal injections approved by the China state FDA for treating
anti-viral indications.   Cease Enuresis Soft Gel is approved by the China
state FDA as a prescription remedy for chronic bedwetting and nighttime
urination. Bedwetting is a serious problem affecting millions of children
and adults. Leveraging on our Cease-Enuresis Soft Gel and the newly
established research center, we believe the Company can capture a
substantial market share of serving patients suffering from enuresis or chronic
bedwetting syndrome

PBN is the smaller of the CompanyÂ's two divisions. PBN products are
not licensed by the China state FDA, but they generally require local
government approval and are typically sold over the counter at the retail
outlets. AOBOÂ's PBN division products soybean peptide products in
powder and liquid forms. Soybean peptide is a cholesterol-free
energy-boosting protein source that enhances the immune system and has anti-fatigue
benefits. AOBO also produces a line of nutritional products through the
PBN division, including the Three-Happiness nutritional drink, which
are rich in vitamins and amino acids to enhance well-being and to provide
energy The Three-Happiness product line is a recognized retail brand
name in China.

AOB owns a very recognizable brand in China with their Three-Happiness
nutritional beverages and the soy protein peptide line, and  have
developed and own two growing products within the PBP market, all of which
will benefit from further market penetration and expansion.

Their strategy is to grow organically by focusing on new product
development and expanding the application of PBP products. This strategic
component involves further penetrating existing markets, capitalizing on
the favorable macrodemographic trends, and expanding the established
distribution network.

How does this boil down to dead Presidents and Franklins?  You want the
truth?  You canÂ't handle the truth!  In November, AOB reported their
3rd quarter results for 2006:

Third Quarter 2006 Highlights:

-- Organic Revenue Growth of 63% during the Quarter
-- Consolidated Gross Margins improve 3.5% versus last year to 66.9%
-- Management Expects Fourth Quarter Revenue to be in the range of $37
million to $39 million and at least $0.15 in EPS

For the third quarter 2006, the Company reported revenues of $27.1
million, an increase of 101.9 percent compared to $13.4 million in the
third quarter of last year. The increase in total revenues for the quarter
from last year was driven by strong organic growth in the Company's
Plant-based Pharmaceutical (PBP) and Plant-based Nutraceutical (PBN) line
of products and as a result of continuing momentum from the acquisition
of Guangxi Lingfeng Pharmaceutical Co. Ltd. (GLP) earlier this year.
During the third quarter, PBP sales, including GLP products, increased by
130.5 percent to $19.9 million compared to the third quarter last year.
Sales of the Company's Cease Enuresis Soft Gel and Patch increased
117.8 percent to $6.6 million as compared to last year with sales of the
Company's Shuanghuanlian Injection Powder increasing 51.5 percent to $6.5
million.

We all know it makes money, but will this move the stock price? 
Remember the mantraÂ...earnings earnings  earnings.    ANAL-ysts say that AOB
will earn $0.10/share next quarter, $0.43/share for this year and
$0.58/share for next year.  Excuse me while I siss in my pants laughing.  AOB
is growing its revenues sequentially EACH QUARTER.  This growth is
ACCELERATING.  This is revenue growth, not just earnings growth.  Their
making it because their selling more stuff which means that their fixed
costs become smaller and smaller per unit sales so their overall margin
gets larger and larger.  The growth rate is ridiculous.  Why?

SimpleÂ...IÂ'm smarter than the ANAL-ysts and can determine this with my
Wharton MBA training. In July 2006, the company acquired HQPL, a
distributor of pharmaceutical products throughout China, for approximately $4
million.  This acquisition will substantially broaden the number of
distribution points for its product portfolio form 10,000 to 100,000, and
will enable AOB to sell throughout all regions of China.  This was
BRILLIANT strategy.
They can and will sustain this growth for at least another 3 quarters,
which $$$MR. MARKET$$$ says will earn them $0.46/share in 2006 on
revenues of $108 million.  When their products hit the street from these new
outlets, 2007 revenues will balloon to $206 million with EPS of $1.03. 
If you take the forward PE that the ANAL-ysts gave us (22) and multiply
it by $1.03, you get a share price of $22.66 which is well past my
target price. 
The boss is so excited I think he hasta go siss.

"I am pleased to report that our business continues to experience
strong momentum as we reported the highest quarterly revenue and net income
in the Company's history as we continue to penetrate the Chinese market
and reinvigorate consumer brand awareness for GLP products in the
women's health market," commented Tony Liu, Chairman and CEO of AOB. "We are
pleased with the performance of our most recent initiatives, which
include increased advertising and the expansion of our distribution
channels through the acquisition of HQPL, as AOB becomes a recognized brand
across China. We believe our orders for GLP products scheduled for
delivery in the fourth quarter will exceed our projection of $6 million
announced at the end of September."

Mr. Liu concluded, "Based on improving visibility and confidence in our
business we are going to begin providing quarterly revenue and earnings
per share guidance beginning with our fourth quarter 2006 results. At
this time we expect the fourth quarter revenue to be in the range of $37
million to $39 million with diluted earnings per share of at least
$0.15, which would represent approximately 88 percent to 98 percent revenue
growth from the comparable quarter last year with EPS increasing
approximately 67 percent versus last year."

This guy ainÂ't no dummy.   Liu holds an EMBA degree and is an
experienced entrepreneur. He was in the military for over 19 years and held a
high rank commander position when he was with the PeopleÂ's Liberation
Army. After Mr. Liu left the army, he started working for the government
of Heilongjiang province. Mr. Liu accumulated and possesses many years
of working experience while he witnessed and participated in the
massive macro economic changes in China. Mr. Liu was one of the
representatives to the National PeopleÂ's Congress. During the last thirteen years,
Mr. Liu has led and managed the Company as its Chief Executive Officer.
He has more than ten years of experience in managing pharmaceutical
companies. Mr. Liu was named the Outstanding Chinese Entrepreneur of the
World and he is currently the Vice Chairman of the International Chinese
Entrepreneur Association.
I guess if he eats his products, he wonÂ't have to go to the Â"looÂ" in
the middle of the night.  Ha ha ha.  I murder me!

Let me know what you think of this write up.  I always like to hear
from you, and frankly I don't even know if you read down this far or if
you even get my email, so drop me a line.

If you liked the write up, send it on to three friends.

If you really liked it, go to this website:

http://www.golittletigers.com .

These kids are working hard to make their football team something
special, and they need your help (I'm the acting President of its Booster
Club and I want to do a good job..this is REALLY important to me).

I am HUGE!!

$$$MR. MARKET$$$

http://www.mrmarketishuge.com

[snowcat]

Drops 10% - the Mr. Market curse is alive & well

[JKN]

Mr. Market is proof that if you hold long enough, the stock will recover.

[la-onda]

American Oriental Bioengineering 'Posts Very Encouraging Q3FY06 Results,' 'Buy/4' Rating Reiterated, Target Raised To $12, In 'Institutional' Research Update By Investrend Analyst Lytel
Wednesday January 3, 3:14 pm ET

NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate) In a report dated November 30, 2006, American Oriental Bioengineering (AMEX: AOB - News) was as "Buy/4," with an increased target valuation of $12, beating analyst's expectations, reporting revenues of $27 million, net income of $7.6 million and EPS of $0.12 in an "Institutional" Update by Investrend analyst Kipley J. Lytel, CFA.

The full report, including important disclosures and disclaimers, is available at http://www.investrendresearch.com. In the report, the analyst also stated:

"The robust revenue growth stems both from acquisitions and from organic growth. AOB has been aggressively promoting its products, employing a Chinese celebrity for its advertising campaign, while acquisitions have helped expand the distribution network and product portfolio. The company reported that backlog for GLP's Jinji Series of products for Q4FY06 stood at $6 million.

"Two of AOB's products have been included in Chinese government's International Traditional Chinese Medicine Program for Cooperation in Science and Technology, which should provide the company with additional visibility factor and possibly will provide the company access to some government facilities or support. Also, the company has hired a new director, Lawrence S. Wizel, who has several decades of experience in Deloitte & Touche. Finally, AOB is moving its corporate headquarters, a move which in the long run may help the company better expand its business and control costs.

"As a result of the stellar growth and improved outlook, we have updated our valuation and price target, which has been increased to $12, representing gain potential of approximately 20%."

All Investrend Research reports published for AOB, including important disclosures and disclaimers, are also available via the company's InvestorPower(TM) Page, posted at Investrend.com (http://www.investrend.com). InvestorPower(TM) Pages are directly accessible from http://www.investrend.com/company/list.asp?sPathParam=yes. Investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.

AOB is enrolled in Investrend Research's pioneering professional research program, which facilitates independent analysts to provide coverage for shareholders in companies that otherwise would have little or no analyst following.

Enrollment fees for Institutional coverage were $36,890, and the fees have been paid by the company. Analysts are paid in advance of initial reports by Investrend Research to eliminate pecuniary interest, and neither the analyst nor anyone associated with Investrend Research may own or trade in the stocks of a company under coverage.

[la-onda]

soon MACD crossing should give AOB some more positive momentum

[la-onda]

There is an article about AOB in tomorrow's Investor's Business Daily in the Health & Medicine Section:

----

American Oriental Bioengineering Shenzhen, China
bioaobo.com

If you've ever read an instruction manual for a Chinese company's product, you know the English can be imprecise. Even a company's namecan get lost in translation. Take American Oriental Bioengineering AOB. The Chinese maker of herbal traditional medicines doesn't do bioengineering, says Wilfred Chow, vice president of finance. The term bioengineering was simply an a name recommended to the firm when it sought its first stock market listing in the U.S. in 2002.

Translated into Chinese, 'bioengineering' would be more like health technology, Chow said. Though American Oriental has yet to start selling in the U.S., the company has embraced the American free-market system. Since 2002 American Oriental has migrated from an OTC stock to the Amex to the New York Stock Exchange, where it began trading on Dec. 18. Since its Amex debut in August 2005, the stock has gone from less than 2 to more than 12.
The listing on the NYSE gave the company a prestige factor, Chow said. While U.S. markets have stricter regulation than those in China, the U.S. rules are at least clear. In China, regulations mean what politicians and bureaucrats say they mean. American Oriental's culture emphasizes hard work, says analyst Julie Chen of Brean Murray, Carret & Co. Plants run 24 hours a day. Chen expects staffers to work right through Chinese New Year on Feb. 17, the biggest annual holiday. Much of the drive comes from Chief Executive Tony Liu, leader of the management team that took the company out of government hands in 1994. Liu, a former Chinese combat officer, maintains military discipline.

In China you need to run a company like an army to succeed, Chow said.

THE FINANCIALS
American Oriental Bioengineering has boosted annual earnings every year since 2002. Analyst Chen expects the company to post 2006 profit of 45 cents a share, up from 31 cents a year earlier. She sees 2007 earnings reaching 58 cents. When Chen initiated coverage in October she had a target price of $9. In December she raised that to $16.

THE COMPANY
American Oriental produces pharmaceutical products and dietary supplements based on plants. It targets the rural Chinese market. The company was founded in 1970 by the Chinese government as Three Happiness Bioengineering. It does almost no research and development, leaving that work to hospitals and universities. American Oriental buys technology and commercializes it. The fragmentation of the Chinese market gives the firm its growth opportunities, Chen says, and its modern business methods give it an edge over competitors. Unable to keep up, competitors are willing to sell out to American Oriental. More acquisitions are likely.

LOOKING AHEAD
The company plans to start selling its products in the U.S. in 2007. It plans to go global thereafter. Asian countries are likely to accept Chinese traditional remedies readily, Chow says. American Oriental is looking for partners in the U.S. and abroad to distribute the products.

Peter Benesh

[ScottishTrader]

Oliver, how long have you been holding AOB?  You must be very happy with it, I'm sure of that.  I didn't even realise they moved to the NYSE!!

Chart is just a thing of beauty, and I can't believe you have been giving us excellent and timely updates on it the whole time, and yet it hasn't garnered the attention it deserves!!  I can't believe I have had AOB on my monitor for the last 6 months and have just let it pass me by!!!

Anyway, AOB shows no sign of stopping, and I may look at picking some up near the ascending support line this week if possible.  Do you know when they are expected to report?

Cheers, and good trading to ya!
ST